Stocks That Hit 52-Week Lows On Monday
During Monday's session, 56 companies made new 52-week lows.
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.
EXCLUSIVE: The Benzinga Moneymaker Series — 5 Emerging Stocks For Investors To Watch
Investors are on the hunt for undervalued, underfollowed and emerging stocks to spot opportunities.
The rise of social media and retail traders gave way to countless methods to uncover new information. For some, this is overwhelming.
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical machining.
Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday’s Mid-Day Session
Gainers
Taboola.com Ltd. (NASDAQ: TBLA) shares gained 52.5% to $2.8050 after the company announced it entered into a 30-year exclusive commercial agreement with Yahoo.
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers
Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67 million.
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday’s Mid-Day Session
Gainers
LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.